Foscarnet en la retinitis por citomegalovirus
- Suárez de Figueroa,
- García, C.
- Montilla, P.
- Hermida, J.M.
ISSN: 0365-6691
Year of publication: 1991
Volume: 60
Issue: 3
Pages: 339-344
Type: Article
More publications in: Archivos de la Sociedad Española de Oftalmologia
Abstract
Six patients with active C.M.V. retinitis and acquired immune deficiency syndrome were treated with the new antiviral drug, Foscarnet (trisudium phosphonoformate). The rate of relapse on maintenance therapy with 100 mg/kg/24 h. seven days per week, was 33% (2/6). In contrast to Ganciclovir, Foscarnet did not induce neutropenia but it produced kidney toxicity that led to reversible renal insufficiency in one case. A decrease of hemoglobin concentration greater than 20%, changes in serum calcium and phosphorous levels were not noted in any patient.